X4 Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
XFOR Nasdaq 8731 https://www.x4pharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for X4 Pharmaceuticals Inc

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 2nd, 2023 8:05 pm
X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome - May 16th, 2023 8:01 pm
X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market - May 16th, 2023 12:30 pm
Weekly biotech pulse: X4 Pharma data on deck, AbbVie set for FDA review - May 15th, 2023 8:44 am
X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update - May 4th, 2023 10:05 am
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) largest shareholders are retail investors with 42% ownership, institutions own 32% - Apr 26th, 2023 4:32 pm
X4 Pharmaceuticals to Report First-Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 4, 2023 - Apr 26th, 2023 12:01 pm
X4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM Phase 3 Clinical Data Accepted for Oral Presentation at the 2023 Annual Meeting of the Clinical Immunology Society (CIS) - Apr 12th, 2023 12:00 pm
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2022 Earnings Call Transcript - Mar 24th, 2023 11:36 am
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Corporate Update - Mar 21st, 2023 10:05 am
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2022 Financial Results and Host a Conference Call and Webcast on March 21, 2023 - Mar 7th, 2023 1:01 pm
What Makes X4 Pharmaceuticals (XFOR) a New Buy Stock - Jan 31st, 2023 5:00 pm
X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia - Dec 12th, 2022 1:30 pm
X4 Pharmaceuticals Prices $65.0 Million Public Offering - Dec 7th, 2022 1:43 pm
X4 Pharmaceuticals Announces Proposed Public Offering - Dec 6th, 2022 11:26 pm
X4 Pharmaceuticals Shares Tumble After Phase 3 Data From Rare Immune Deficiency Candidate - Nov 30th, 2022 1:05 pm
X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM Syndrome - Nov 29th, 2022 9:01 pm
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) most popular amongst individual investors who own 40% of the shares, institutions hold 34% - Nov 17th, 2022 2:51 pm
X4 Pharmaceuticals to Present at Stifel Healthcare Conference - Nov 8th, 2022 1:00 pm
X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Nov 3rd, 2022 10:05 am